Researchers are raising awareness about Guillain-Barré syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) during GBS CIDP Awareness Month, marking 110 years since GBS was first identified. The GBS CIDP Foundation International has launched a campaign called “GBS: 110 Years, 110 Stories,” which aims to share personal experiences from individuals affected by these rare neurological disorders. The campaign encourages people to visit a new website to share their stories, fostering a sense of community and support among those impacted by GBS and CIDP.

For those interested in healthy aging, understanding GBS and CIDP is crucial, especially since these conditions can affect anyone, regardless of age or background. GBS affects about 2 in every 100,000 people annually, while CIDP has a prevalence of approximately 9 in 100,000. These conditions can lead to significant challenges, including weakness and sensory loss, making awareness and support vital for those facing these issues. By sharing stories, the campaign emphasizes the importance of connection and the need for advancements in care.

The campaign is still in its early stages, with many stories yet to be collected and shared. While the awareness efforts are promising, the research and understanding of GBS and CIDP continue to evolve. The collaboration between the GBS CIDP Foundation and Annexon Biosciences aims to highlight the real-life impact of these disorders and the urgency for improved treatment options. As the campaign progresses, it serves as a reminder that more work is needed to support individuals living with GBS and CIDP.

Source: globenewswire.com